Држава: Канада
Језик: Енглески
Извор: Health Canada
OLANZAPINE
NU-PHARM INC
N05AH03
OLANZAPINE
7.5MG
TABLET
OLANZAPINE 7.5MG
ORAL
100/500
Prescription
ATYPICAL ANTIPSYCHOTICS
Active ingredient group (AIG) number: 0128783004; AHFS:
CANCELLED (UNRETURNED ANNUAL)
2018-03-28
PRODUCT MONOGRAPH PR NU-OLANZAPINE Olanzapine Tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg Antipsychotic Agent NU-PHARM INC. DATE OF PREPARATION: 50 Mural Street, Units 1 & 2 OCTOBER 8, 2009 Richmond Hill, Ontario L4B 1E4 Control No.: 121691 Page 2 of 57 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION....................................................... 3 SUMMARY PRODUCT INFORMATION.............................................................................. 3 INDICATIONS AND CLINICAL USE .................................................................................. 3 CONTRAINDICATIONS ........................................................................................................ 4 WARNINGS AND PRECAUTIONS ...................................................................................... 4 ADVERSE REACTIONS ....................................................................................................... 11 DRUG INTERACTIONS........................................................................................................ 25 DOSAGE AND ADMINISTRATION ................................................................................... 27 OVERDOSAGE...................................................................................................................... 28 ACTION AND CLINICAL PHARMACOLOGY.................................................................. 29 STORAGE AND STABILITY .............................................................................................. 31 DOSAGE FORMS, COMPOSITION AND PACKAGING................................................... 31 PART II: SCIENTIFIC INFORMATION ............................................................................. 33 PHARMACEUTICAL INFORMATION ............................................................................... 33 CLINICAL TRIALS ............................................................................................................... 33 DETAILED PHARMACOLOGY ................................ Прочитајте комплетан документ